ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 200... ( PLYMOUTH Minn. May 2 /- ev3 Inc. ...)

ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 2008 Guidance

Date:5/2/2008

PLYMOUTH, Minn., May 2 /PRNewswire-FirstCall/ -- ev3 Inc. (Nasdaq: EVVV), a global endovascular device company, today reported financial results for its fiscal first quarter of 2008 and its revised financial guidance for 2008.

As previously reported, ev3's net sales were $101.3 million in the first quarter of 2008 representing a 65% increase over the same quarter of the prior year and a 10% increase over the fourth quarter of 2007. The increase in net sales over the same quarter of the prior year was primarily attributable to the acquisition of FoxHollow. The sequential quarter increase in net sales was driven by growth in the pre-FoxHollow acquisition peripheral vascular business segment and the neurovascular business segment. However, first quarter net sales results were negatively impacted by greater than anticipated sales force integration challenges related to the FoxHollow acquisition and elevated customer inventory levels of SilverHawk products.

Robert Palmisano, president and chief executive officer of ev3 Inc., commented, "While we believe that our fundamental strategies are sound, we have much work ahead of us to improve our execution and efficiency. My top priority will be to continue expanding our position in the peripheral vascular and neurovascular markets globally by offering a full complement of innovative therapies, investing in the development of our next generation of products and pursuing a broad clinical trial agenda to bring new products to market and further validate the scientific foundation of our endovascular procedures. I believe these initiatives will in turn drive growth and shareholder value."

Palmisano commented further, "In resetting our guidance, we took into account the factors that could affect our business in 2008, including the performance of our U.S. atherectomy business, which continues to be adversely affected by elevated customer inventory levels of SilverHawk, the ability of our U.S. peripheral va
'/>"/>

SOURCE ev3 Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12
Related biology technology :

1. United Therapeutics Reports First Quarter 2008 Financial Results
2. Endocare Reports 2008 First Quarter Financial Results
3. AMICAS Reports Financial Results for the First Quarter Ended March 31, 2008
4. LeMaitre Vascular Reports Q1 2008 Revenue of $11.8 Million, a 20% Increase
5. Anadys Pharmaceuticals Reports First Quarter 2008 Financial Results and Highlights
6. Neurobiological Technologies Reports Receipt of $2.0 Million Royalty Payment for Quarterly Sales of Memantine
7. Alexion Reports First Quarter 2008 Results
8. Masimo Reports First Quarter 2008 Financial Results
9. Cardium Reports on Science Channel Series Featuring InnerCools Endovascular Cooling During Brain Surgery at Stanford University
10. Cynosure Reports 41% Revenue Increase: 10th Consecutive Quarter of Revenue Growth
11. SuperGen Reports 2008 First Quarter Financial Results

Post Your Comments:

(Date:5/15/2012)... AUSTIN, Texas, May 15, 2012 Vermillion, Inc. ... company, reported financial and operational results for the first ... Operational Highlights , In Q1, the volume ... help differentiate benign from malignant ovarian masses, was generally ... the quarter and demonstrated an increase of 28% to ...

(Date:5/15/2012)... 2012 Reportlinker.com announces that ... available in its catalogue: , ... and Market Forecast to 2019 ... Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment ... Summary GlobalData, the industry analysis ...

(Date:5/15/2012)... May 15, 2012 Generex Biotechnology Corporation (OTCBB: ... pivotal Phase III trials, is pleased to announce today ... of its wholly-owned subsidiary, Antigen Express, Inc., has been ... in clinical trial research and immuno-therapeutic treatments of breast ... Indiana University School of Medicine ...

(Date:5/15/2012)... BGI, one of the world,s ... GS FLX+ System has been successfully installed at its ... the existing array of short read sequencing technologies and ... GS FLX+ System, developed by 454 Life Sciences, a ... exceptional accuracy and high-throughput, making the system well suited ...

[0] Vermillion Reports First Quarter 2012 Results [0] Neuroendocrine Carcinoma Therapeutics - Pipeline Assessment and Market Forecast to 2019 [0] Generex Enhances Antigen Express Scientific Advisory Board for the AE37 Breast Cancer Vaccine with Renowned Breast Cancer Researchers [0] BGI Installs Roche GS FLX+ System to Enhance Long Read Sequencing Capabilities for Genome and Transcriptome Research

... April 30 Tigris Pharmaceuticals, Inc., a privately held ... on its novel molecule, AFP-464, during the recent AACR ... represents a significant advancement in the treatment of Triple ... of invasive breast cancer," stated Edmundo Muniz, M.D., Ph.D., ...

... Educational Webinar "How Organizations Can Make the Transition to ... Virtify, Inc. , , CAMBRIDGE, Mass., April ... the market leader in Enterprise Content Compliance solutions for ... ), a provider of Enterprise Compliance and Quality Management ...

... 30 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals, Inc. (NASDAQ: ... for the first quarter ended March 31, 2009. , ... first quarter in what has been a difficult business ... and CEO of Angiotech. "Sales in our proprietary Surgical ...

Tigris Pharmaceuticals Presents Results of Breast Cancer Research at AACR Annual Meeting Event Alert: 'SPL R4 Compliance and its Impact on Regulatory Submission Processes'Angiotech Pharmaceuticals, Inc. announces financial results for the first quarter ended March 31, 2009

(Date:5/21/2012)... Institution (WHOI) have conducted a new study to measure ... Ocean. The study, recently published in the journal ... understand the Arctic Ocean,s carbon cyclethe pathway through which ... It will also offer an important point of reference ... time, and how the ecosystem responds to rising global ...

(Date:5/21/2012)... Woesik, Florida Institute of Technology professor of biological ... the National Science Foundation for research into the ... develop quantitative approaches to assess the clustering of ... the corals. When diseases cluster they are usually ... cause of infection., Although diseases are one of ...

(Date:5/21/2012)... the National University of Singapore,s (NUS) Department of Biological ... compound a compound that is undergoing preclinical trials ... of energy and stop them from growing into a ... This is the first time a research group has ... formation. , Building on the new findings, the ...

Breaking Biology News(10 mins):New study by WHOI scientists provides baseline measurements of carbon in Arctic Ocean 2 New study by WHOI scientists provides baseline measurements of carbon in Arctic Ocean 3 Novel discovery by NUS scientists paves the way for more effective treatment of cancers 2 Many Parents in the Dark About Drug Resistant Infections 3A Study 76703 1 Many Parents in the Dark About Drug Resistant Infections 3A Study 76703 2 Former FDA Inspectors Train Medical Device Pharmaceutical Companies How to Comply with Latest FDA Expectations for Validation and Part 11 17786 1 Former FDA Inspectors Train Medical Device Pharmaceutical Companies How to Comply with Latest FDA Expectations for Validation and Part 11 17786 2 Regenicin to Present Live at RetailInvestorConferences com on November 4th 17784 1 Regenicin to Present Live at RetailInvestorConferences com on November 4th 17784 2

[0] New study by WHOI scientists provides baseline measurements of carbon in Arctic Ocean [0] Florida Tech biological sciences professor earns $257,000 NSF grant to study coral diseases [0] Novel discovery by NUS scientists paves the way for more effective treatment of cancers

... requires many years of growth before a tree is ready ... Now, scientists at universities in Sweden and the United States ... , In the annual plant Arabidopsis, the first plant to ... Locus T (FT) induce flowering in response to day length. ...

... ants, most people prefer to wipe the venomous little varmints off ... own back yards. The reviled South American native that invaded the ... circles as Solenopsis invicta and everywhere else as a painful pest ... Tschinkel. , An ardent fire ant fan and one of its ...

... a lawnmower, the Holy Grail of horticultural accomplishment would be ... Now, that vision of suburban bliss -- and more -- ... pathway that regulates the stature of plants. In addition to ... the development of sturdier, more fruitful crop plants such as ...

Other Biology News:Scientists discover that ancient genes dictate flowering, fall bud set 2 Fire ants: Their true story told by the scientist who loves them 2 Fire ants: Their true story told by the scientist who loves them 3 No-mow grass may be coming to your yard soon 2 No-mow grass may be coming to your yard soon 3

Scientists discover that ancient genes dictate flowering, fall bud set Fire ants: Their true story told by the scientist who loves them No-mow grass may be coming to your yard soon

...

Rabbit polyclonal to XTP4 ( Abpromise for all tested applications). entrezGeneID: 84299 SwissProtID: Q9BRT3...

Chicken polyclonal to QPRT ( Abpromise for all tested applications). Antigen: Synthetic peptide, corresponding to Internal sequence amino acids 123-237 of Human QPRT Entrez Gene ID: 23475 ...

Biology Products:

Acrylamide, Molecular Biology Grade from Research Organics, Inc.Acrylamide from Research Organics, Inc.Rabbit Anti-XTP4 Polyclonal Antibody, Unconjugated from Abcam Chicken Anti-Human QPRT Polyclonal Antibody, Unconjugated from Abcam

ev3 Inc. Reports 2008 First Quarter Financial Results and Revised 200...( PLYMOUTH Minn. May 2 /- ev3 Inc. ...)